JP2023545992A5 - - Google Patents

Info

Publication number
JP2023545992A5
JP2023545992A5 JP2023520531A JP2023520531A JP2023545992A5 JP 2023545992 A5 JP2023545992 A5 JP 2023545992A5 JP 2023520531 A JP2023520531 A JP 2023520531A JP 2023520531 A JP2023520531 A JP 2023520531A JP 2023545992 A5 JP2023545992 A5 JP 2023545992A5
Authority
JP
Japan
Prior art keywords
cells
domain
receptor
cell
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023520531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545992A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/054302 external-priority patent/WO2022076910A1/en
Publication of JP2023545992A publication Critical patent/JP2023545992A/ja
Publication of JP2023545992A5 publication Critical patent/JP2023545992A5/ja
Pending legal-status Critical Current

Links

JP2023520531A 2020-10-09 2021-10-08 操作されたiPSC及び装備された免疫エフェクター細胞 Pending JP2023545992A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063090113P 2020-10-09 2020-10-09
US63/090,113 2020-10-09
US202163172383P 2021-04-08 2021-04-08
US63/172,383 2021-04-08
PCT/US2021/054302 WO2022076910A1 (en) 2020-10-09 2021-10-08 Engineered ipsc and armed immune effector cells

Publications (2)

Publication Number Publication Date
JP2023545992A JP2023545992A (ja) 2023-11-01
JP2023545992A5 true JP2023545992A5 (enExample) 2024-10-17

Family

ID=81125515

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520531A Pending JP2023545992A (ja) 2020-10-09 2021-10-08 操作されたiPSC及び装備された免疫エフェクター細胞

Country Status (9)

Country Link
US (1) US20240033355A1 (enExample)
EP (1) EP4225785A4 (enExample)
JP (1) JP2023545992A (enExample)
KR (2) KR20250161670A (enExample)
AU (1) AU2021358110A1 (enExample)
CA (1) CA3194850A1 (enExample)
IL (1) IL301983A (enExample)
MX (1) MX2023004130A (enExample)
WO (1) WO2022076910A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
KR20240013094A (ko) 2021-03-17 2024-01-30 마이얼로이드 테라퓨틱스, 인크. 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054520A2 (en) * 2014-10-03 2016-04-07 The California Institute For Biomedical Research Engineered cell surface proteins and uses thereof
US11667691B2 (en) * 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
WO2018014039A1 (en) * 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
BR112020011017A2 (pt) * 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
EP3715368A1 (en) * 2019-03-28 2020-09-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells
CN112480263B (zh) * 2019-09-12 2026-06-05 百欧恩泰(苏州)医药有限公司 一种双特异t细胞激活器活化t细胞的设计及其应用

Similar Documents

Publication Publication Date Title
JP2022541441A5 (enExample)
JP2022550899A5 (enExample)
JP2022548943A5 (enExample)
JP2021505131A5 (enExample)
JP2022510207A5 (enExample)
JP2023548467A5 (enExample)
JP2023549098A5 (enExample)
JP2023530704A5 (enExample)
JP2021519061A5 (enExample)
JP2023505206A5 (enExample)
JP2023548829A5 (enExample)
JP7623020B2 (ja) 同種異系移植のための操作された免疫細胞
JP7767502B2 (ja) Nk阻害性分子を発現する遺伝子改変免疫細胞とその使用
Maher Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
CN114015656A (zh) 用于同种异体移植的工程化免疫细胞
KR20210018838A (ko) 유전자 조작된 세포 및 응용
KR20210126008A (ko) 세포 면역 치료의 조합
KR20230137923A (ko) 신규한 키메라 항원 수용체 및 이의 용도
US20220133792A1 (en) Signaling platforms for chimeric antigen receptor t cells
JP2021501587A (ja) Cd38指向性キメラ抗原受容体構築物
JP2024515920A5 (enExample)
KR20250161670A (ko) 조작된 iPSC 및 보강된 면역 효과기 세포
JP2024526237A5 (enExample)
CN115785279A (zh) 包含新型共刺激结构域的嵌合抗原受体及其用途